PART I Business Overview We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Our commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. To complement our internal research and development, we also actively evaluate in-licensing and acquisition opportunities for commercial products, p...
Q2 FY2026 — expected 2026-08-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-19 | 2025-12-31 | 0001104506-26-000009 | EDGAR | 91K words |
| 2025-02-20 | 2024-12-31 | 0001104506-25-000009 | EDGAR | — |
| 2024-02-22 | 2023-12-31 | 0001104506-24-000008 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0001104506-23-000009 | EDGAR | — |
| 2022-02-17 | 2021-12-31 | 0001104506-22-000008 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001104506-21-000005 | EDGAR | — |
| 2020-02-25 | 2019-12-31 | 0001104506-20-000007 | EDGAR | — |
| 2019-02-22 | 2018-12-31 | 0001104506-19-000009 | EDGAR | — |
| 2018-02-23 | 2017-12-31 | 0001104506-18-000002 | EDGAR | — |
| 2017-02-23 | 2016-12-31 | 0001047469-17-000856 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-05-07 | 2026-03-31 | 0001104506-26-000032 | EDGAR | — |
| 2025-10-30 | 2025-09-30 | 0001104506-25-000053 | EDGAR | 36K words |
| 2025-08-07 | 2025-06-30 | 0001104506-25-000043 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001104506-25-000026 | EDGAR | — |
| 2024-10-31 | 2024-09-30 | 0001104506-24-000033 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001104506-24-000026 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001104506-24-000016 | EDGAR | — |
| 2023-10-26 | 2023-09-30 | 0001104506-23-000025 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001104506-23-000018 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001104506-23-000012 | EDGAR | — |
| 2022-10-27 | 2022-09-30 | 0001104506-22-000023 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001104506-22-000019 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-05-15 | 0001140361-26-021648 | EDGAR | — |
| 2026-05-07 | 0001140361-26-019430 | EDGAR | — |
| 2026-04-07 | 0001140361-26-013659 | EDGAR | 1K words |
| 2026-03-23 | 0001140361-26-010651 | EDGAR | — |
| 2026-02-19 | 0001140361-26-006116 | EDGAR | — |
| 2026-01-09 | 0001140361-26-000778 | EDGAR | — |
| 2025-12-17 | 0001140361-25-045836 | EDGAR | — |
| 2025-11-18 | 0001140361-25-042598 | EDGAR | — |
| 2025-10-30 | 0001140361-25-039789 | EDGAR | — |
| 2025-08-12 | 0001140361-25-030537 | EDGAR | — |
205 total filings indexed. 173 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001104506 |
| Ticker | INSM |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | VA |
| Website | https://www.insmed.com |
| Listed | 2000-06-01 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report